Scientists uncover mutations that make cancer resistant to therapies targeting KRAS

Cancer drugs that inhibit the protein expressed by a mutated form of the KRAS gene might be approved later this year, but cancer cells often develop additional mutations that make them resistant to such targeted drugs. Investigators have identified some of these mutations in a patient and identified strategies to overcome them.